An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

Pervasis Therapeutics Announces Promising Efficacy Results from Phase 1 and 2 Clinical Trials of Vascugel® in Dialysis Patients Needing Permanent AV Access, Data Builds on Compelling Safety Findings ...

Amplifi Vascular announced that it received breakthrough device designation for its Amplifi Vein Dilation System.

FAIRWAY, Kan.--(BUSINESS WIRE)--Flow Forward Medical Inc. (Flow Forward), a medical device company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality ...

Please provide your email address to receive an email when new articles are posted on . According to recently published results, insurance-related disparities in the use of arteriovenous fistulas and ...

SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive findings from the randomized AVF ...

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...

This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...

CRESSKILL, N.J.--(BUSINESS WIRE)--Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to ...

The arteriovenous fistula remains the “gold standard” in vascular access placement for patients on hemodialysis, clinicians said in interviews with Nephrology News & Issues. “When they work well, ...